Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells

Maria Carmen Rodenas, Julia Peñas-Martínez, Irene Pardo-Sánchez, David Zaragoza-Huesca, Carmen Ortega-Sabater, Jorge Peña-García, Salvador Espín, Guillermo Ricote, Sofía Montenegro, Francisco Ayala-De La Peña, Ginés Luengo-Gil, Andrés Nieto, Francisco García-Molina, Vicente Vicente, Francesco Bernardi, María Luisa Lozano, Victoriano Mulero, Horacio Pérez-Sánchez, Alberto Carmona-Bayonas, Irene Martínez-Martínez

Open source

DOI: 10.3389/fmolb.2023.1182925
Published: 2023-05-19
Container: Frontiers in Molecular Biosciences
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fmolb.2023.1182925,
  title = {Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells},
  author = {Maria Carmen Rodenas and Julia Peñas-Martínez and Irene Pardo-Sánchez and David Zaragoza-Huesca and Carmen Ortega-Sabater and Jorge Peña-García and Salvador Espín and Guillermo Ricote and Sofía Montenegro and Francisco Ayala-De La Peña and Ginés Luengo-Gil and Andrés Nieto and Francisco García-Molina and Vicente Vicente and Francesco Bernardi and María Luisa Lozano and Victoriano Mulero and Horacio Pérez-Sánchez and Alberto Carmona-Bayonas and Irene Martínez-Martínez},
  year = {2023},
  journal = {Frontiers in Molecular Biosciences},
  doi = {10.3389/fmolb.2023.1182925},
  url = {https://doi.org/10.3389/fmolb.2023.1182925}
}

RIS

TY  - JOUR
TI  - Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells
AU  - Maria Carmen Rodenas
AU  - Julia Peñas-Martínez
AU  - Irene Pardo-Sánchez
AU  - David Zaragoza-Huesca
AU  - Carmen Ortega-Sabater
AU  - Jorge Peña-García
AU  - Salvador Espín
AU  - Guillermo Ricote
AU  - Sofía Montenegro
AU  - Francisco Ayala-De La Peña
AU  - Ginés Luengo-Gil
AU  - Andrés Nieto
AU  - Francisco García-Molina
AU  - Vicente Vicente
AU  - Francesco Bernardi
AU  - María Luisa Lozano
AU  - Victoriano Mulero
AU  - Horacio Pérez-Sánchez
AU  - Alberto Carmona-Bayonas
AU  - Irene Martínez-Martínez
PY  - 2023
JO  - Frontiers in Molecular Biosciences
DO  - 10.3389/fmolb.2023.1182925
UR  - https://doi.org/10.3389/fmolb.2023.1182925
ER  -

APA

Rodenas, M. C., Peñas-Martínez, J., Pardo-Sánchez, I., Zaragoza-Huesca, D., Ortega-Sabater, C., Peña-García, J., Espín, S., Ricote, G., Montenegro, S., Peña, F. A. L., Luengo-Gil, G., Nieto, A., García-Molina, F., Vicente, V., Bernardi, F., Lozano, M. L., Mulero, V., Pérez-Sánchez, H., Carmona-Bayonas, A., & Martínez-Martínez, I. (2023). Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2023.1182925

Source records

crossref · retrieved 2026-09-26T12:05:16.735Z